If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
86
results.
Updated on
15/07/2026 [07:35:00]
Results 25 to 50 of 86
Absstract of: US20260174873A1
Compositions of nucleases in formulations with dendrimers are used in pharmaceutically effective dosages as therapeutics for covid-19 and a broad spectrum of viruses in various embodiments. When cationized nucleases are mixed and/or complexed with a dendrimer, an unexpected positive dendrimer effect is manifest. This positive dendrimer effect is shown to be highly effective for catalyzing anti-viral RNase properties. In various embodiments compositions of cationized nucleases in combination with a dendrimer demonstrated this synergistic amplification of anti-viral effectiveness and are used in pharmaceutically effective dosages as therapeutics against covid-19 and a broad spectrum of viruses. An exemplar formulation which exhibits a positive dendrimer effect is cationized RNase A mixed and/or complexed with gen 2 PAMAM dendrimer.
Absstract of: US20260177549A1
0000 Provided herein are methods, diagnostic instruments, and kits for detecting the presence or absence of an analyte associated with a disease in a subject. In some embodiments, the disease is Lyme disease, SARS-CoV-2, or a human immunodeficiency virus infection.
Absstract of: EP4763985A1
The present invention concerns the creation of antisense oligonucleotides (ASOs) with no cytotoxicity that are very active as therapeutic agents in knocking down the replication of SARS-CoV-2 in human cells with pan activity against all known past and current variants.
Absstract of: KR20260095805A
본 발명은 사스 코로나 바이러스 2 변이체의 스파이크 단백질에 특이적인 결합 분자 및 이의 용도에 관한 것이다. 보다 구체적으로는, 본 발명의 결합 분자는 사스 코로나 바이러스 2(SARS-CoV-2) 변이체의 스파이크 단백질(Spike protein)의 RBD(Receptor binding domain) 영역에 특이적인 결합 능력을 가지고, 사스 코로나 바이러스 감염증에 대한 치료제와 비교하여 우수한 중화 활성을 나타냄을 확인하였는 바, 사스 코로나 바이러스 감염증에 대한 예방 또는 치료에 활용될 수 있다.
Absstract of: US20260166160A1
Described are proteolysis targeting chimeras (PROTACs) for use in managing and treating infectious disease. Described compositions can be used to inhibit viral replication associated with coronavirus, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus disease 2019 (COVID-19). Methods of synthesizing PROTACs are described. Example PROTAC compositions are provided, including dual targeting compounds having a main protease (Mpro) ligand attached to a linker, an E3 ligase ligand attached to the linker, and a papain-like protease (PLpro) inhibitor attached to the linker. PROTAC compounds useful for degrading Mpro activity and/or PLpro activity, and useful for treating coronavirus infections such as COVID-19, are described.
Absstract of: US20260167674A1
Peptide sequences that are ACE2 homologues are provided. Compared to the wild-type ACE2 in the host, the peptide sequences bind with higher affinity to the receptor-binding domain (RBD), thus inhibiting this interaction by competitively inhibiting the binding of the virus RBD region of SARS-COV-2 with the human ACE2. The peptide sequences can be included in a pharmaceutical composition.
Absstract of: WO2026123076A1
The field of the specification relates broadly to Middle East respiratory syndrome coronavirus vaccine (MERS-CoV) antigens and methods of using and manufacturing MERS-CoV antigens. The invention also relates to vaccines, kits, devices and strips comprising the MERS-CoV antigen. The invention also relates to ribonucleic acids encoding a S protein monomer of a coronavirus vaccine (MERS-CoV) antigen and methods of using and manufacturing the ribonucleic acid. The invention also relates to vectors, lipid nanoparticles, RNA vaccines, kits, devices and strips comprising the ribonucleic acid.
Absstract of: US20260167734A1
Monoclonal antibodies that specifically bind to and block the function of Fas ligand (FasL) are described. The FasL-specific antibodies can be used for the development of therapeutics for the treatment of diseases, disorders and conditions associated with the Fas/FasL signaling pathway, such as cancer, sepsis, ischemia-reperfusion injury, and coronavirus disease 2019 (COVID-19).
Absstract of: WO2026126237A1
The present invention relates to (E)-5-alkoxy-1- phenylpentan-1-one O-(2-(N,N- disubstitutedamino)ethyl) oximes and the methods of preparation thereof. The present invention describes the (E)-5-alkoxy-1-phenylpentan-1-one O-(2-(N,N- disubstitutedamino)ethyl) oximes as potent anti-COVID-19 agent.
Absstract of: EP4759833A1
The present invention relates to proteins, adenoviruses and vaccines against infection by SARS-CoV-2 Omicron XBB subvariants, which belongs to the medicine field. To address the lack of effective prophylactic and therapeutic drugs for preventing and/or treating infections by SARS-CoV-2 Omicron XBB variants and subvariants thereof, the present invention provides proteins, adenoviruses and vaccines for preventing and/or treating infection by SARS-CoV-2 Omicron XBB subvariants, wherein these vaccines are optimized and designed based on a full-length S protein, and the receptor-binding domain (RBD) and receptor-binding domain and heptad repeat (RBD-HR) sequences in the S protein of the SARS-CoV-2 Omicron XBB subvariants, specifically, XBB.1.16, XBB.1.5, XBB.1.16.6, BA.2.86, EG.5, JN.1, XBB.2.3 and XBB.2, and are capable of aiding the host in combating coronavirus infections, and particularly have a relatively good preventive and therapeutic effect against cross-infections caused by SARS-CoV-2 Omicron XBB subvariants.
Absstract of: EP4759827A2
The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
Absstract of: LU604195B1
This invention discloses a spatiotemporal deep learning model for forecasting the development of sudden epidemics, taking into consideration meteorological factors. The method formulates the short-term prediction problem of regional new COVID-19 cases as a predictive technical issue involving multidimensional, gridded spatiotemporal sequences for both input and prediction targets. To address this, a ConvLSTM spatiotemporal deep model is constructed for predicting COVID-19 case numbers. Furthermore, the model is enhanced by considering the modifying effects of meteorological elements, creating a comprehensive spatiotemporal model called the Meteor-ConvLSTM model that integrates historical meteorological factors. This spatiotemporal model produces timely, downscaled, and high-resolution prediction results. This invention is characterized by high predictive accuracy and strong practicality, making it useful for guiding relevant authorities in understanding the epidemic situation and adjusting decision-making strategies.
Absstract of: US20260158492A1
The present invention describes kits and methods for rapid detection of nucleic acid sequences in real-time and in any setting. Unique features of this kit include isothermal nucleic acid extraction in Unit 1, and amplification, labeling, and signal detection in Unit 2 (FIG. 1). These units can be operated separately with manual transfer of product from one to the other or can be put together in a fashion where user places sample into inlet of Unit 1 and observes results in detection chamber of Unit 2. Several versions of this kit can be developed using different sequence-specific primers and probes to detect any nucleic acid sequence (DNA or RNA) in a multiplex fashion. In a preferred embodiment, visual detection of amplified signal is done using Lateral Flow Strips, eliminating the need for any additional complex equipment. Such a kit can be easily developed and manufactured to assist in the mitigation response to any pandemic, especially for COVID-19. The COVID-19 kit is called an At-Home COVID test (AH-COV).
Absstract of: US20260159544A1
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof, a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Absstract of: US20260158134A1
Immunogenic compositions and methods of use thereof, for eliciting an immune response against multiple coronaviruses, using a single vaccine composition are described. The compositions include an antigen from more than one pathogen, for example, more than one member of the β-coronavirus family, for example, SARS-CoV and MERS-CoV. Exemplary antigens include the receptor binding domain (RBD) of the coronavirus spike protein or a fragment thereof. The disclosed compositions are administered to a subject in need therefore, to generate an immune response against more than one pathogen, represented by the source of the antigens in the construct.
Absstract of: US20260159553A1
The present invention provides an expression vector comprises gene of interest encode more than one structural protein to enhance immune responses against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and its variants. Furthermore, the expression vector to produce mRNA expresses more than one structural protein to generate immune response against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and its variants.
Absstract of: US20260158015A1
The present invention relates to a compound comprising a compound having formula (I) below:wherein R1, R2 and R3 are as defined, or a pharmaceutically acceptable salt thereof, for use in the prevention or in the treatment of an infection.The invention also relates to a pharmaceutical composition comprising the compound, for use in the prevention or in the treatment of an infection.
Absstract of: US20260157987A1
A viral inactivation composition includes an aqueous solution of citric acid and L-arginine hydrochloride with a pH below 3.5. The citric acid and L-arginine hydrochloride are present in amounts that directly inactivate COVID-19, influenza, and common cold virus in a human upper respiratory system. A method of directly inactivating COVID-19, influenza, and common cold virus in the human upper respiratory system includes administering the viral inactivation composition to a subject. These ingredients are safe, non-toxic, and very effective.
Absstract of: US20260158135A1
0000 The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.
Absstract of: WO2026122604A1
The present invention is directed to method of synthesis of (1R,2S,5S)-N-(1S)-1-cyano-2- (2-oxoindolin-3-yl)ethyl-3-(2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetyl)aminobutanoyl-6,6- dimethyl-3-azabicyclo3.1.0hexane-2-carboxamide, which are useful in the treatment of coronavirus infection including COVID-19 resulting from SARS-CoV-2 infection.
Absstract of: US20260158044A1
0000 A composition for the treatment of COVID-19 is disclosed, including a first composition including approximately 10 mg of dexamethasone. The first composition is combined with a second composition including between approximately 48 mg to approximately 80 mg of triamcinolone acetonide, sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80.
Absstract of: US20260158055A1
The present invention involves a novel method for treatment of coronavirus infection, including SARS-COV-2. The method comprises administering stannous protoporphyrin and/or cyanocobalamin to a human patient at risk for developing complications from coronavirus infection. The method is particularly useful where a patient has been diagnosed with coronavirus infection or has been exposed to coronavirus but has not developed symptoms of coronavirus infection.
Absstract of: WO2025029797A1
Methods of assigning a COVID pathological type for a subject suffering from COVID-19 are provided. Aspects of the methods include assigning a COVID pathological type for the subject based on a determined quantitative, multiplex cytokine/chemokine panel in a test sample from the subject. Also provided are methods of treating a subject (e.g., a long hauler subject) for chronic COVID-19. Aspects of such methods include administering to the long hauler subject a CCR5/CCL5 interaction inhibitor to treat the long hauler subject. Also provided are compositions for use in practicing the methods. The methods and compositions find use in a variety of applications, including patient stratification, treatment and therapy determination and therapy response assessment.
Absstract of: US20260151476A1
0000 Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-COV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.
Nº publicación: US20260152531A1 04/06/2026
Applicant:
RESEARCH INST AT NATIONWIDE CHILDRENS HOSPITAL [US]
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Absstract of: US20260152531A1
0000 Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.
BOPI
Electronic site
